Article Details

After axing a top drug, Millendo bags a PhII replacement with biotech buyout

Retrieved on: 2017-12-19 20:56:15

Tags for this article:

Click the tags to see associated articles and topics

After axing a top drug, Millendo bags a PhII replacement with biotech buyout. View article details on hiswai:

Excerpt

<div>Interestingly, the license for the now-defunct MLE4901 came in conjunction with a $62 million Series B backing led by <b>New Enterprise Associates</b>. According to Xconomy, investors were hesitant to close the deal until Millendo got MLE4901 in its pipeline. But that program was somewhat short lived.</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo